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Abstract: Oral administration of sapropterin hydrochloride, recently approved for use by the 
US Food and Drug Administration and the European Commission, is a novel approach for the 
treatment of phenylketonuria (PKU), one of the most common inborn errors of metabolism. 
PKU is caused by an inherited deficiency of the enzyme phenylalanine hydroxylase (PAH), and 
the pathophysiology of the disorder is related to chronic accumulation of the free amino acid 
phenylalanine in tissues. Contemporary therapy is based upon restriction of dietary protein intake, 
which leads to reduction of blood phenylalanine levels. This therapy is difficult to maintain 
throughout life, and dietary noncompliance is commonplace. Sapropterin dihydrochloride is a 
synthetic version of tetrahydrobiopterin, the naturally occurring pterin cofactor that is required 
for PAH-mediated phenylalanine hydroxylation. In a subset of individuals with PAH deficiency, 
sapropterin administration leads to reduction in blood phenylalanine levels independent of dietary 
protein. For these individuals, sapropterin is an effective novel therapy for PKU.
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Introduction
Dietary restriction of phenylalanine intake has been the mainstay of therapy for 
  phenylketonuria (PKU), one of the most common inborn errors of metabolism, for the 
past 50 years. With the recent US Food and Drug Administration (FDA) and European 
Commission approvals of sapropterin dihydrochloride (Kuvan®, BioMarin   Corporation, 
Tiburon, CA), a new era in PKU treatment has begun. Sapropterin dihydrochloride is a 
synthetic version of the naturally occurring pterin cofactor,   tetrahydrobiopterin (BH4). 
In a subset of individuals with PKU, sapropterin treatment substantially reduces blood 
phenylalanine levels independent of dietary phenylalanine intake. For these so-called 
“BH4-responsive” patients, sapropterin therapy provides the benefit of improved disease 
control and may even eliminate the need for dietary therapy completely in individuals 
with milder forms of hyperphenylalaninemia.
Biology of phenylketonuria  
and tetrahydrobiopterin
PKU has an annual incidence of about 1:16,000 births in the US.1 PKU is caused by 
recessively inherited mutations in the PAH gene that encodes the enzyme   phenylalanine 
hydroxylase (PAH). PAH is predominantly expressed in liver (but also kidney and 
  pancreas) and catalyzes the irreversible hydroxylation of phenylalanine, an essential 
amino acid, to tyrosine (Figure 1). PAH is a homotetramer that requires iron and 
  molecular oxygen as well as the unconjugated pterin cofactor, BH4, for catalytic   activity. Biologics: Targets & Therapy 2010:4 submit your manuscript | www.dovepress.com
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BH4 is synthesized de novo from   guanosine   triphosphate 
in several tissues, including liver, but is also recycled after 
  phenylalanine hydroxylation through   enzymatically-  catalyzed 
reduction.2 Inherited deficiency of BH4 synthesis or recycling 
enzymes is the cause of   hyperphenylalaninemia in approxi-
mately 2% of infants detected through newborn screening. 
Treatment of these children frequently requires chronic 
oral or parenteral BH4 administration in addition to dietary 
  phenylalanine restriction.
PAH deficiency leads to accumulation of   phenylalanine 
in all tissues of the body and relative deficiency of tyrosine. 
Untreated PKU is associated with chronic hyperphenyla-
laninemia, microcephaly, mental retardation, epilepsy, relative 
hypopigmentation, growth delay, and eczema.   Fortunately, 
all infants in the US and most Western countries are screened 
for hyperphenylalaninemia at 24–72 hours of life. Initiation 
of therapy early in life prevents the major manifestations of 
the disease. Contemporary therapy is based upon the restric-
tion of dietary phenylalanine intake through the reduction of 
dietary protein. Under this   regimen,   synthetic medical foods 
must be consumed in order to provide adequate intake of total 
energy and amino acids other than   phenylalanine.   Intellectual 
outcome is directly related to success in reducing blood 
  phenylalanine levels,3 and restriction of dietary phenylalanine 
is recommended throughout the life of the individual with 
PKU.4 However, this therapeutic approach is complicated, 
  unpalatable, and difficult to   maintain through adolescence 
and into adulthood. Loss of dietary control may be associated 
with   deterioration of cognitive performance and attention 
span, resulting from development of a   neurodegenerative 
disease of white matter,5 and in pregnant women with PKU 
and elevated blood phenylalanine, severe teratogenesis with 
fetal growth failure, microcephaly, mental retardation, and 
congenital heart disease, ie, the so-called maternal PKU 
  syndrome.6 For all of these reasons, novel alternatives to 
dietary therapy are being sought.
History of tetrahydrobiopterin 
responsiveness in phenylketonuria
Individuals with inherited PAH deficiency have normal biop-
terin content in blood and urine, but Kure et al reported that 
oral administration of additional BH4 to some individuals 
with mild hyperphenylalaninemia led to a significant reduc-
tion in blood phenylalanine levels without altering dietary 
phenylalanine content.7 Several other investigators have 
subsequently confirmed this observation.8–17 The basis of 
BH4 responsiveness may be related to different molecular 
mechanisms. Increased liver BH4 content may simply stimu-
late the activity of mutant partially active PAH enzyme18 or 
it may act as a chemical chaperone to stabilize mutant PAH 
monomers.19 Proof of this latter mechanism is provided by 
investigation of other small molecules that act as chaperones 
to stabilize mutant PAH.20 Some specific PAH mutations are 
known to affect the affinity of the PAH enzyme for its biop-
terin cofactor.21 In patients with these specific mutations, oral 
biopterin administration may overcome this block and restore 
enzymatic activity. In reality, only a few such mutations 
have been shown to be often (but not invariably) associated 
with BH4 responsiveness in PKU patients22,23 while other 
mutations, such as the R408W mutation, are consistently 
associated with nonresponsiveness. BH4 responsiveness in an 
individual PKU patient cannot always be accurately predicted 
from their PAH genotype.22,24
Clinical trials of sapropterin  
in phenylketonuria
After the discovery that some PKU patients could benefit 
from BH4 supplementation, few patients were able to avail 
themselves of this treatment option because the worldwide 
supply of BH4 was limited and detailed pharmacokinetic 
studies had not been performed. In the USA, BH4 was 
approved by the FDA only for use as an investigational drug. 
To overcome this problem, BioMarin Corporation (Novato, 
CA) initiated a specific effort to develop and intensively study 
sapropterin dihydrochloride ((6R)-2-amino-6-[(1R, 2S)- 
1,2-dihydroxypropyl]-5,6,7,8-tetrahydro-4(3H)-pteridinone 
dihydrochloride, Figure 2), a biologically active synthetic 
form of BH4, in subjects with PKU. Sapropterin dihydro-
chloride is supplied in airtight blister packs as 100 mg tablets 
that may be administered whole or dissolved in water or 
apple juice. The tablets contain ascorbic acid to maintain 
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Figure  1  Phenylalanine  hydroxylation.  Phenylalanine  is  hydroxylated  to  tyrosine 
through the catalytic activity of phenylalanine hydroxylase, which requires the presence 
of  the  unconjugated  pterin  cofactor,  tetrahydrobiopterin  (BH4).  Sapropterin  is  a 
synthetic form of BH4 that augments the endogenous BH4 supply.  During phenylalanine 
hydroxylation, BH4 is oxidized to quinonoid dihydrobiopterin (qBH2). Fully active BH4 
is regenerated through the sequential action of pterin-4a-carbinolamine dehydratase 
and dihydropteridine reductase (DHPR) or may be synthesized de novo from guanosine 
triphosphate (GTP).2Biologics: Targets & Therapy 2010:4 submit your manuscript | www.dovepress.com
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the reduction status of sapropterin and allowing storage at 
room temperature. In patients with PKU who are   responsive 
to sapropterin, daily oral administration of sapropterin 
leads to a sustained decrease in blood phenylalanine levels 
  without alteration of dietary phenylalanine intake. The mean 
half-life of elimination of sapropterin from the blood is 
6.7 (range 3  –17) hours in PKU patients.25 The specific 
mechanism of elimination for sapropterin dihydrochloride 
has not been published, but abundant data concerning the fate 
of orally administered natural BH4 in humans and animals 
demonstrate that BH4 is quickly sequestered in the liver or 
excreted in urine.26
To determine the actual prevalence of BH4   responsiveness, 
an open-label, screening study was performed in 490 indi-
viduals with PKU enrolled at 30 treatment centers in the US 
and Europe.27 Blood phenylalanine levels were greater than 
450 µM (normal range 35–150 µM) in all subjects at the begin-
ning of the study, signifying less than ideal disease   control 
on standard dietary therapy. Sapropterin   dihydrochloride, 
10 mg/kg body weight, was administered orally once per 
day for eight days. Subjects were instructed not to alter 
their typical dietary protein intake during the study. Blood 
phenylalanine levels were measured prior to sapropterin 
treatment and again on day 8, and “BH4   responsiveness” was 
defined as a 30% reduction in blood phenylalanine. Overall, 
20% of study subjects (96/485 subjects who completed the 
entire eight-day trial) responded to sapropterin treatment. 
Among all responders, blood phenylalanine levels decreased 
to 391.8  ± 185.3 µM (mean ± 1 standard deviation) after 
eight days of sapropterin administration. When   stratified 
by blood phenylalanine level prior to initiating therapy, a 
higher proportion of individuals with mild PKU responded 
to sapropterin. In these subjects, 54% and 24% with initial 
blood levels of 450–600 µM or 600–900 µM, respectively, 
responded to sapropterin. Somewhat surprisingly, 10% 
of subjects with initial phenylalanine levels greater than 
900 µM also responded, with at least a 30% reduction in 
blood phenylalanine. For standard dietary therapy in young 
children with PKU, the target range for blood phenylalanine 
during treatment is commonly 120–360 µM. Approximately 
10% of subjects with PKU in this   screening trial achieved a 
reduction in blood phenylalanine to the accepted   treatment 
target range on sapropterin alone without any change in 
dietary phenylalanine intake. An additional 10% of the 
study population achieved a clinically significant reduction 
in blood phenylalanine, but phenylalanine levels remained 
above 360 µM. No severe adverse effects of sapropterin 
therapy were reported.
Once the prevalence of BH4-responsive hyperphenyla-
laninemia was established, a Phase III, randomized, double-
blind, placebo-controlled trial28 was initiated to evaluate fully 
the efficacy of sapropterin treatment.   Sapropterin-responsive 
subjects identified in the Phase II trial were randomly 
assigned to receive either sapropterin 10 mg/kg once per day 
or placebo for six weeks. At the end of the trial, no   serious 
adverse events were reported in either study group, and 
the incidence of minor events was equal in the two study 
groups. By the end of the   six-week trial, blood phenylala-
nine in the sapropterin treatment group (n = 40 subjects) 
decreased from 842.7 ± 299.6 µM to 606.9 ± 377.0 µM 
on average. The mean change in blood phenylalanine was 
-235.9 ± 257.0 µM over six weeks on sapropterin com-
pared with a change of only +2.9 ± 239.5 µM in the control 
group (n = 47 subjects). The estimated difference between 
the two groups was -245 ± 52.5 µM (P = 0.0002). Over the 
course of the study, 44% of subjects on sapropterin had a 
sustained reduction in blood phenylalanine greater than 30% 
from baseline compared with only 9% of controls. Prior to 
initiation of the trial, only 17% of subjects exhibited blood 
phenylalanine levels below 600 µM. In the sapropterin treat-
ment group, 54% of subjects achieved blood phenylalanine 
below 600 µM. Blood phenylalanine decreased to less than 
360 µM in 32% of subjects.
BH4 responsiveness has been predicted to occur only in 
patients who carry at least one mutant PAH allele that yields 
some residual PAH enzyme activity.18 Among sapropterin-
responsive subjects in the Phase III trial, PAH genotyping 
was available for 17 subjects, and non-null PAH mutations 
were detected on at least one allele in 16 of 17 subjects. 
However, in the seventeenth subject, both PAH alleles carried 
severe mutations that would not appear to permit   expression 
of residual PAH activity, yet this subject responded to 
  sapropterin treatment. Sapropterin responsiveness in the 
study subjects was not linked to any specific PAH mutation. 
Two reviews suggest that genotype can predict to some 
degree whether a patient with PKU will be responsive to BH4 
but that ultimately only BH4 challenge will fully ascertain 
BH4 responsiveness.23,24
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In a third clinical trial, 80 sapropterin-responsive subjects 
participated in a multicenter, open-label extension study.29 
The initial phase of the trial was a forced dose titration study, 
with subjects receiving doses of 5, 20, and 10 mg/kg/day 
of sapropterin consecutively for two weeks each. This was 
followed by a four-week period of 10 mg/kg/day and then 
a 12-week fixed dose extension. In the last phase, subjects 
received one of three different sapropterin doses (5, 10, or 
20 mg/kg/day) based upon their individual responses in the 
dose titration phase of the study. In the first phase, although 
plasma phenylalanine levels decreased from week 0 at all 
sapropterin doses, a dose-response relationship was demon-
strated, with significantly lower plasma phenylalanine levels 
on average during treatment with 10 or 20 mg/kg/day than 
when the subjects received only 5 mg/kg/day. During the 
fixed-dose extension phase, six subjects (8%) responded to 
5 mg/kg/day, while 37 subjects (46%) received 10 mg/kg/day, 
and 37 subjects (46%) received 20 mg/kg/day. The choice of 
dose and the reduction in phenylalanine levels achieved by 
22 weeks clearly reflect a dichotomy in the severity of PKU 
in the study subjects. Individuals with higher phenylalanine 
levels at baseline required more drug to effect a decrease in 
blood phenylalanine, and the drop in phenylalanine level 
achieved was not as satisfactory as that demonstrated by 
subjects responding to either 5 or 10 mg/kg/day. Overall, 
plasma phenylalanine decreased by 190.5 µM (±355.7) in 
all dose groups after 22 weeks of drug. The mean plasma 
  phenylalanine level at the end of 22 weeks in the 20 mg/kg 
dose group was 895.7 (±407.2) µM while mean phenylala-
nine levels in the 5 and 10 mg/kg dose groups were 437.8 
(±260.5) µM and 449.9 (±193.1) µM, respectively.   Individuals 
with a lower baseline phenylalanine level (a measure of dietary 
phenylalanine tolerance) showed greater responsiveness to 
the drug. Only 50%, 49%, and 42% of subjects in the 5, 10, 
and 20 mg/kg dose groups, respectively, achieved a 30% 
decrease in plasma phenylalanine from baseline at the end of 
the 22 weeks. Recall that all study subjects had demonstrated a 
30% reduction in plasma phenylalanine over eight days in the 
initial screening study. Unintended changes in dietary protein 
intake over the course of the trials (further protein restriction 
during the screening trial or liberalization of dietary protein 
intake during the extension trial) would have affected these 
results. There were no minor or severe adverse events attribut-
able to sapropterin treatment in the trial. This extension study 
  demonstrates that sapropterin   treatment may safely reduce 
plasma phenylalanine concentrations in a dose-dependent 
manner in BH4-responsive individuals. Furthermore, empiric 
use of the drug for one month or more may be needed.
The effectiveness of sapropterin treatment has also been 
examined in 90 children aged 4–12 years with PKU while they 
continued on a protein-restricted diet.30 Of these   subjects, 56% 
experienced a 30% reduction in blood phenylalanine levels after 
eight days of sapropterin treatment. After the challenge period, 
all responders were offered participation in a placebo-controlled 
trial during which dietary phenylalanine intake was gradually 
increased. In the group receiving sapropterin, dietary phenylala-
nine tolerance doubled on average, with no significant increase 
in blood phenylalanine levels in comparison with phenylalanine 
tolerance prior to sapropterin treatment, while dietary phenyla-
lanine tolerance increased only slightly in the placebo group. 
Again, no significant safety issues were revealed.
Based on the accumulated study data, the FDA approved 
sapropterin dihydrochloride for clinical use in December 
2007. Marketing authorization for sapropterin has sub-
sequently been granted in Japan (July 2008) and Europe 
(December 2008), and is under expedited review in Canada. 
In Europe, sapropterin has been licensed for use in children 
with PAH deficiency over the age of four years, and also in 
individuals of all ages with hyperphenylalaninemia due to 
congenital BH4 deficiency. In the US, sapropterin treatment 
is approved in all age groups and in pregnant women, even 
though sapropterin has not been formally studied in children 
under four years age or during pregnancy. Limited experience 
with administration of other commercially available forms 
of BH4 during pregnancy suggests that no adverse effects 
are to be expected.31 In the case of the pregnant woman 
with BH4-responsive PKU, the well documented risks to the 
fetus associated with maternal hyperphenylalaninemia likely 
outweigh any putative risks of sapropterin treatment. Still, 
these issues deserve further study and BioMarin has initiated 
a voluntary registry system to accumulate data on the use of 
sapropterin in young children and during pregnancy.
Post-approval clinical use  
of sapropterin
Now that sapropterin has gained FDA approval, the task ahead 
is to determine which PKU patients will benefit most from 
this novel therapeutic approach and how to best introduce this 
medication into a specific patient’s dietary treatment regimen. 
Sapropterin has been formally proven in research studies 
to lower blood phenylalanine levels in individuals who are 
responsive, but limited data are   available concerning the effect 
of sapropterin treatment on actual protein tolerance. Can the 
sapropterin-treated patient safely increase their dietary protein 
intake and maintain blood   phenylalanine levels within a des-
ignated treatment range? Also, long-term safety and cognitive Biologics: Targets & Therapy 2010:4 submit your manuscript | www.dovepress.com
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outcomes should be evaluated in patients who will probably 
be treated with sapropterin for many years.
The determination of whether a specific patient with 
PKU is truly BH4-responsive is clearly key to the decision 
about adding sapropterin to the patient’s treatment   regimen. 
To some degree, the definition of “responsiveness” is an arbi-
trary one. For the purposes of the screening study, responsive-
ness was defined as a 30% decrease in plasma phenylalanine 
after an eight-day trial of oral sapropterin at 10 mg/kg/day. 
As we have seen, subsequent evaluations have revealed both 
false-positive and false-negative results from this screening 
procedure. Some individuals who met criteria for responsive-
ness during the screening trial subsequently did not maintain 
a therapeutic effect from sapropterin over the longer term. 
Some individuals who did not meet criteria for responsiveness 
with a sapropterin dose of 10 mg/kg/day were later found to 
be responsive to the higher dose of 20 mg/kg/day. It has been 
suggested that BH4   responsiveness would require a patient 
with PKU to carry at least one PAH mutant allele that allows 
for residual enzyme activity.18 However, in the clinical trial, a 
few individuals who were found to be sapropterin-responsive 
carried PAH mutations that were predicted to yield severe 
PAH deficiency. A recent comprehensive review suggests that 
genotype can predict to some degree whether a patient with 
PKU will be responsive to BH4, but that ultimately only BH4 
challenge will fully ascertain BH4 responsiveness.24
In addition to the eight-day screening trial employed in 
the clinical trial,27 several other BH4 challenge protocols 
have been described in the literature, and these have recom-
mended differing BH4 doses, different durations of challenge, 
determination of blood phenylalanine levels at different 
times, varying percentage reductions in blood phenylalanine 
required to define BH4 responsiveness and, in some cases, 
challenging the subject with a standardized amount of dietary 
phenylalanine along with BH4. This topic has been reviewed.32 
Recent published data have revealed that the decrease in blood 
phenylalanine following a single BH4 dose obeys a first-order 
kinetic model only over the first eight hours after BH4 admin-
istration.33 Accordingly, a single BH4 loading test (20 mg/kg) 
with monitoring of blood phenylalanine at 0, 8, 12, and 24 
hours has been proposed as an evaluation of responsiveness.34 
If blood phenylalanine dropped more than 20% in the short 
term, then a   several-week trial with BH4 dose adjustment to 
maintain optimal phenylalanine levels would be warranted.
A rational algorithm for testing BH4 responsiveness in 
a routine clinical setting has been proposed35 and a similar 
protocol has been endorsed by clinicians in Europe.36 This 
algorithm evaluates both the short-term response to BH4 
administration (allowing for upward adjustment of dietary 
phenylalanine intake if blood phenylalanine levels fall dra-
matically after BH4 treatment) and the longer-term efficacy of 
sapropterin treatment. In this algorithm, blood phenylalanine 
is measured prior to sapropterin administration and on days 1, 
7, 14, and 28 days following sapropterin 20 mg/kg/day. The 
sapropterin dose may be decreased or dietary phenylalanine 
increased if blood phenylalanine levels decrease below the 
target range. Responsiveness is not defined by any specific 
percentage decrease in phenylalanine but rather by whether 
the decrease in phenylalanine is thought by the clinician and 
patient to be clinically meaningful. Continued sapropterin 
treatment is warranted if blood phenylalanine levels are low-
ered into a specific target range defined by clinician and patient 
and is particularly relevant if dietary phenylalanine restriction 
can be relaxed without increasing blood phenylalanine. This 
testing algorithm allows for the individualization of therapy 
and flexibility in the assessment of BH4 responsiveness.
Cost of sapropterin
The cost of sapropterin therapy versus the PKU diet must also 
be considered. As a drug with an orphan product designation, 
the costs of drug development for sapropterin are distributed 
among a relatively small patient population. The cost of daily 
sapropterin therapy at the highest dose of 20 mg/kg/day is US 
$100,000 to $150,000 for the average adult patient versus the 
cost of the phenylalanine-restricted diet, including the use of 
medical foods, which is typically US $15,000 to $20,000 per 
year. The PKU patient and their clinician must consider these 
factors when deciding whether to employ sapropterin therapy.
Conclusions
The systematic evaluation of sapropterin responsiveness in a 
PKU population and the subsequent commercial availability of 
a validated form of BH4 have now provided a new therapeutic 
option for phenylketonuria. As discussed, continuance of strict 
dietary therapy throughout life is recommended but is practi-
cally difficult. Compliance with this recommendation in adults 
is often poor. For a subset of individuals with PKU, sapropterin 
will be essential as sole therapy. For other patients, sapropterin 
treatment may not completely eliminate the need for dietary 
therapy, but may increase a patient’s dietary protein tolerance, 
allowing a significant improvement in daily quality of life. The 
introduction of sapropterin for widespread clinical use repre-
sents an exciting time in the evolution of therapy for PKU.
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